Davis Polk Advises Warner Chilcott on Its Acquisition by Actavis
Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in a stock-for-stock transaction. The transaction is expected to close by the end of 2013. Warner Chilcott is a specialty pharmaceutical company currently focused on the women’s healthcare, gastroenterology, urology and dermatology segments of the […]
Davis Polk Advises Warner Chilcott on Its Acquisition by Actavis Read More »